Radiation Oncology/RTOG Trials

Overview of RTOG Trials RTOG Website Links Please visit The RTOG Website for the latest trials and protocol information. RTOG dose constraints List of RTOG published trials List of RTOG abstracts (ASTRO and ASCO) RTOG scientific sessions RTOG newsletter RTOG meeting minutes - divided by site committee 11702729 (2001) - "RTOG Publications since 1996" — IJROBP Vol 51 No 3 Suppl 2, 125-145, 2001. "RTOG manuscripts and abstracts submitted for publication: As of May 2001" — IJROBP Vol 51 No 3 Suppl 2, 146-8, 2001. Finding RTOG trial results From NCI Website: Search for RTOG Trial (change the number for the trial you're searching for) - provides list of publications Advanced Search - For any clinical trial. Be sure to set status of trial as active/closed; useful parameters include cooperative group, protocol id, and type of cancer. Searching Pubmed for a specific RTOG trial - Search - (change the number to the trial you're searching for) Pages by organ site RTOG Anal Trials RTOG Bladder Trials RTOG Brain Trials RTOG Cervix Trials RTOG Esophageal Trials RTOG Pancreas Trials RTOG Prostate Trials RTOG NSCLC Trials RTOG SCLC Trials RTOG Liver Trials RTOG Melanoma Trials RTOG Sarcoma Trials See also: 7558966 (1995) — "Evolution and accomplishments of the Radiation Therapy Oncology Group." Cox JD et al. Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):747-54. 7635796 (1995) — "The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer." Byhardt RW et al. Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1513-25. 8655364 (1996) — Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer." Fu KK et al. Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):425-38. 10-XX and later 10-14 Protocol (PDF) (ongoing) - Breast - Phase II. Repeat breast preserving surgery and 3D-CRT PBI for local recurrence 10-16 Protocol (PDF) - Oropharynx - Phase III. Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer 00-XX to 09-XX 09-37 Protocol (PDF) (ongoing) - SCLC - Extensive stage. Phase III. PCI vs PCI + consolidative extra-cranial RT 09-26 Protocol (PDF) (ongoing) - Bladder - Phase II. T1. Selective bladder preservation chapter link 09-21 Protocol (PDF) (ongoing) - Endometrium - Phase II. IMRT + concurrent cisplatin/bevacizumab + adjuvant carboplatin/paclitaxel 09-20 (ongoing) - H&N - A phase III randomized trial of surgery followed by radiotherapy (IMRT) +/- cetuximab for intermediate risk HN SCCA 09-15 Protocol (PDF) (ongoing) - NSCLC - Phase II randomized. SBRT inoperable central lesions 34/1 vs. 48/4 08-15 Protocol (PDF) (ongoing) - Prostate - Phase III randomized. Dose escalated RT ± 6 month ADT 08-13 Protocol (PDF) (ongoing) - NSCLC - Phase I/II. SBRT inoperable peripheral lesions 50/5 -> 60/5 07-24 Protocol (PDF) (ongoing) - Cervix - High risk, early stage pts after Rad Hyst. Adjuvant Chemo/RT +/- adjuvant chemo. 07-12 Protocol (PDF) (ongoing) - Bladder - Phase II randomized. Selective bladder preservation RT + 5FU/cisplatin vs RT + gemcitabine chapter link 06-30 Protocol (PDF) (ongoing - Sarcoma - Phase II. Preop IGRT in the extremity 06-23 Protocol (PDF) - SCLC - Phase II. AHFX 61.2/34 Gy with concurrent cisplatin/etoposide and growth factor support chapter link 06-18 Protocol (PDF) (ongoing) - NSCLC - Phase II. SBRT in operable patients. 60/3 06-17 Protocol (PDF) (ongoing) - NSCLC - Phase III. Standard (60 Gy) vs. High Dose (74 Gy) concurrent with carbo/taxol +/- Cetuximab in Stage IIIA/IIIB 05-38 Protocol Summary (ongoing) - SCLC - Phase III, 3 arms. 45/30 BID vs 70/35 QD vs AHFX 61.2/34. Concurrent cisplatin/etoposide chapter link 05-29 - Anal - Phase II. Dose-painted IMRT chapter link 05-24 (ongoing) - Bladder - A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer. chapter link 05-22 Protocol (PDF) (2005-2009) - H&N - A phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (C225) followed by surgery for residual disease for stage III and IV head and neck carcinomas. 2011: ASCO Abstract 5500 05-21 (ongoing) - Prostate - A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs AS and 3DCRT/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer 05-15 - NSCLC - Comparative study of GTV definition +/- PET scan 04-38 (ongoing) - Liver - Phase I. Dose escalation. 35 Gy in 3.5 Gy/fx -> 50 Gy in 5.0 Gy/fx in patients with metastatic liver cancer. 04-36 Protocol (PDF) (ongoing) -- Esophagus -- Phase III. Non-surgical approach. Paclitaxel + Cisplatin + RT +/- Cetuximab chapter link 04-24 (ongoing) - Glioma - Phase II. High risk LGG (at least 3 risk factors: age >=40, tumor diameter >=6cm, tumor crossing midline, astrocytoma subtype, pre-op neurologic deficit). RT + Temozolomide. Comparison will be to historical EORTC patient population 04-21 (Closed) - Head & Neck - Phase III. Locally recurrent, previously irradiated H&N: Concurrent Re-RT/Chemo vs. Chemo alone Closed due to poor accrual 04-18 Protocol (PDF) (Closed) - Cervix/Endometrial - Phase II. Post-op IMRT. 04-17 Protocol (PDF) (Closed) - Cervix - Phase II. Locally advanced. Definitive RT + cisplatin + bevacizumab. 04-15 (2006-2009) - Prostate - Phase III. Low risk, T1-T2, PSA < 10, G 2-6. Randomized to 73.8 Gy in 41 fractions (1.8 Gy/fx) vs 70 Gy in 28 fractions (at 2.5 Gy/fx). 04-13 / NSABP B-39 (ongoing) Protocol -- "A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer" 04-12 / SWOG S0332 Protocol - NSCLC - NSCLC Stage IIIA (N2) surgically resectable. Induction chemo vs chemo/RT followed by surgery then chemo. Closed due to poor accrual 04-11 (2005-6) - Pancreas - Phase II. RT + bevacizumab + capecitabine, with maintenance gemcitabine and bevacizumab 19636002 (2009) 03-30 Protocol - Sarcoma - Phase II. Preop thalidomide and RT or doxorubicin/ifosfamide/dacarbazine and RT 03-24 Protocol - NSCLC - Phase II. Chemo-RT + Cetuximab in Stage IIIA/IIIB Chapter link 21555682 (2011) 03-21 - Prostate - Intermediate localized PCA. 45 Gy EBRT (no IMRT) + 19 Gy (2 fractions) HDR boost 20207506 (2010): Acceptable toxicity 03-19 Protocol (PDF) - Breast - Phase I/II. 3D-CRT confined to lumpectomy cavity for Stage I and II chapter link 19910132 (2009): Initial efficacy and toxicity comparable 03-15 Protocol (PDF) - Supportive Care - Phase III. Octreotide for diarrhea prevention in anal and rectal cancer chapter link 20339140 (2010): No benefit 02-46 - Esophagus - Phase II. Paclitaxel Based Chemoradiation Regimen With Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer chapter link ASTRO Abstract: Feasible 02-41 - SCLC - Phase I. Irinotectan + cisplatin + RT (45/30 BID or 70/35 QD in limited stage SCLC 02-39 (ongoing) Protocol (PDF) - SCLC' - Phase II. Accelerated high dose RT (61.2 Gy in 5 weeks) with concurrent cisplatin/etoposide in limited small cell lung cancer 02-36 Protocol (PDF) - NSCLC - Phase II. SBRT inoperable patients 60/3 02-35 Protocol link - NSCLC - PET for pre- and post- treatment assessment in locally advanced NSCLC 02-34 (ongoing) - H&N - Post-op. A phase II randomized trial of surgery followed by chemoradiotherapy plus C225 (cetuximab) for advanced squamous cell carcinoma of the head and neck. ASTRO Abstract 2007: RT + cisplatin or docetaxol + cetuximab is safe and feasible 02-33 - Bladder - TURBT followed by induction chemo/RT (BID RT and randomized to Taxol + cisplatin vs 5-FU and cisplatin), evaluate tumor response, then consolidation chemo/RT (BID RT and randomized to same arm as above), then 4 cycles adjuvant chemo (Gemzar, Taxol, Cisplatin). Cystectomy for those who fail induction. chapter link 02-32 (ongoing) - Prostate - Intermediate localized PCA. EBRT + PB vs. PB alone 02-29 Protocol (PDF) (ongoing) - NSCLC - Phase II. IIIA-B, resectable. Preop chemo/RT -> surgery -> additional chemo. 02-25 (2003-2005) Protocol - H&N - Phase II. IMRT use in Nasopharynx chapter link 19564532 (2009): IMRT feasible in multi-institutional setting 02-15 (ongoing) - Prostate - Treatment of ED. Sildenafil x 12 weeks crossover study. 02-14 Protocol (PDF) - NSCLC - PCI vs observation in locally advanced NSCLC 02-13 Protocol (PDF) - NSCLC - Phase I/II. Celebrex with RT in locally advanced NSCLC Closed - poor accrual 02-12 / Intergroup PCI99-01 (1999-2005) Protocol (PDF) - SCLC - PCI with Limited Disease SCLC - Intergroup study. PCI 25 Gy (at 2.5 Gy/fx) vs. 36 Gy (at 2/fx) vs. 36 Gy (at 1.5 BID). chapter link 19386548: No difference in brain mets, worse survival with higher dose 02-11 (2002-2004) GBM - CNS - RT with concurrent/adjuvant gefitinib 23182702: Well tolerated but no benefit over historical controls 01-32 Protocol - Sarcoma - Phase II. GIST. Neoadjuvant and adjuvant Gleevec 01-29 (2002-2005) Protocol (PDF) - H&N - Chemo/RT with conventional RT (70 Gy in 7 weeks) vs chemo/RT with concomitant boost (72 Gy in 6 weeks). Cisplatin (100 mg/m2) on days 1, 22, 43 (conventional) or 1 and 22 (C.B.). Enrolled selected Stage III-IV (T2N2-3M0, T3-4 Any N M0, no T1-2N1 or T1N2-3) chapter link ASTRO 2007: Comparable acute toxicity 01-28 (closed March 2004) Protocol (PDF) - Cervix - Phase I/II. Celecoxib + chemo/RT (cisplatin + 5-FU) for locally advanced cervical cancer, stage IIB-IVA or node-positive IB-IIA. 17482376 (2007), 17084549 (2007), 18299147 (2008), 19509178 (2009) 01-26 (ongoing) - Prostate - High dose 3D-CRT/IMRT randomized to 70.2 Gy vs. 79.2 Gy 01-18 (closed) - Brain Mets - Phase III. WBRT 37.5/15 +/- Thalidomide See chapter for more details 18164847, 2007 - No benefit 01-17 (closed) - NSCLC - Phase I/II. Dose escalation, 3D-CRT + concurrent carboplatin/paclitaxel chapter link 20368547 (2010), 20457350 (2010) 01-16 Protocol (PDF) (2001-2007) - Cervix - Phase I/II. Positive Para-Aortic LN (or high common iliac). Extended field RT +/- Amifostine. 17398031 (2007) 01-14 (closed)(Protocol) - Gastric - Phase II. Randomized comparison of 2 chemo-RT regimens (Induction 5-FU/cisplatin/taxol + concurrent 5-FU/taxol + RT vs. induction cisplatin/taxol + concurrent cisplatin/taxol) chapter link ASTRO 2006 abstract: 5-FU arm too toxic 19273696 (2009) 01-13 (closed) - Esophagus - Phase III. Compares two induction + concurrent chemo/RT regimens) chapter link 18574157 (2008): Both arms too toxic 00-24 (2001-3) - H&N - post-operative chemo/RT. Early Taxol (within post-op day 7-14) then RT to 60 Gy with cisplatin/taxol weekly for the last 3 weeks 19720915 (2009) 00-22 (2001-2005) Protocol (PDF) - H&N - Phase I/II study of conformal and intensity modulated irradiation for oropharyngeal cancer. Stage T1-2, N0-1. chapter link 19540060 (2009): IMRT feasible 00-20 (Closed) - Pancreas - Phase II, weekly gemcitabine + paclitaxel + XRT followed by farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer 00-19 (closed) - Prostate - Intermediate localized PCA. Phase II EBRT + PB 00-17 Protocol (PDF) - NSCLC - Phase I. GEM/paclitaxel vs. GEM/carboplatin and RT for Stage IIIA/B NSCLC 19096311 (2009) 00-15 SWOG S9900 Protocol - NSCLC - Phase III. Surgery vs Neoadjuvant paclitaxel/carboplatin for Stage IB, II, and selected IIIA patients 20231678 00-12 (2001-2003) - Rectum (Protocol (PDF)) - Randomized Phase II. Preoperative chemo/RT. 16446336, 2006 — "Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal Cancer: Radiation Therapy Oncology Group Trial 0012." Mohiuddin M et al. J Clin Oncol, Vol 24, No 4 (February 1), 2006: pp. 650-655. 00-11 (closed) - Prostate - Unfavorable pT3 PCA s/p RP. AST x 2 years alone vs. EBRT + AST x 2 years vs. EBRT alone. Study closed due to non-accrual. 90-XX to 99-XX 99-15 (Closed; pending) (Intergroup/SWOG 9927) - Breast - post-mastectomy RT for Stage II with 1-3 positive LN (T1-2N1) 99-14 (2000-2000) Protocol - H&N - "A phase II trial of concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas." 15860857 (2005): Concomitant boost + concurrent cisplatin is feasible 18640496 (2008): long term results 99-13 (2000-2) Protocol - H&N, Skin Toxicity - "A phase III comparison of Biafine to declared institutional preference for radiation induced skin toxicity in patients undergoing radiation therapy fro advanced squamous cell carcinomas of the head and neck." 16648511 (2006) 99-11 (2000-2003) Protocol (PDF) - H&N - "Phase II Study of Paciltaxel and Cisplatin in Combination with split course concomitant hyperfractionated re-irradiation in patients with recurrent squamous cell cancer of the head and neck." Chapter. 17947728: High incidence of Grade 5 toxicity, but better OS than chemo alone 99-10 (1999-2004) - Prostate - Intermediate risk PCA. AST/2 followed by EBRT/AST vs. AST/7 followed by EBRT/AST. 99-09 (Closed) Protocol - NSCLC - Phase II. Resected Stage II-IIIA, adjuvant RT + vaccine immunotherapy (CeaVac and TriAb) 99-06 (1999-2002) Protocol (PDF) - Bladder - "Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy chapter link 19100600 (2009): Favorable tumor response 99-05 (1999-2003) - Endometrium - A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Paclitaxel Chemotherapy following TAH/BSO for Patients with Endometrial Cancer. Grade 2-3 and Stage IC, IIA (with >50% myometrial invasion), or IIB. chapter link Closed due to poor accrual 99-04 (1999-2004) Protocol (PDF) - Gastric - Phase II. Pre-op chemo and chemo-RT 16921048 (2006) 99-03 (2000-2003) Protocol (PDF) - H&N - RT vs RT + weekly erythropoietin for pts with H&N cancer and anemia chapter link. Closed early due to other published data suggesting a decrease in locoregional control in pts receiving erythropoietin. 17716826 (2007): No difference in outcomes 99-02 (closed early, Oct 2004) - Prostate - High risk, localized PCA. (AST/2 + EBRT) +/- TEE (Paclitaxel, Estramustine, and Etoposide). Study closed due to increased thromboembolic toxicity due to Emcyt. 18990504 (2009) 99-01 (2000-2) - H&N - Phase III, +/- GM-CSF for mucositis during RT. 17293228 (2007) 98-12 (Closed) - Pancreas - Phase II, weekly Taxol + XRT for unresectable pancreatic cancer 14758134 (2004) 98-11 (1998-2005) Protocol (PDF)- Anal - Induction/concurrent chemo/XRT with 5-FU/CDDP vs concurrent chemo/XRT with 5-FU/Mitomycin-C chapter link 18430910 (2008) 98-05 (1998-2000) - Prostate - Phase II, brachytherapy, low risk 17084551 (2007) 98-04 (1999-2006) - Breast Surgery +/- RT for low or intermediate grade DCIS chapter link Closed due to non-accrual 98-03 - CNS / GBM - Dose escalation. 18723297 (2009): Feasible 98-02 (1998-2002) - CNS glioma - A Phase II Study of Observation in Favorable Low-Grade Glioma and A Phase III Study of Radiation with or without PCV Chemotherapy in Unfavorable Low-Grade Glioma. Summary (PDF) 18976072 (2008, Low Risk Group) 98-01 (closed) - Lung NSCLC - +/- Amifostine with hyperfractionated RT with concurrent chemo chapter link 15800308 (2005): No benefit, 18501528 (2008), 19858383 (2009) 97-16 (CALGB 9781) - Esophagus - Trimodality (cisplatin, 5-FU, XRT, surgery) vs surgery alone. Chapter link. Closed early due to nonaccrual 2006 ASCO Abstract: Survival advantage for trimodality therapy 97-14 (closed) - Prostate, Breast, Palliation - Mets to bone. 3 Gy x 10 vs. 8Gy x 1 Conclusion ASTRO 2003 Abstract : "Palliative external beam radiation therapy is very effective in providing pain relief, with complete or partial improvement in pain seen in 66% of patients. Pain and narcotic relief is equivalent for both 30 Gy in 10 fractions and 8 Gy in a single fraction. At 3 months follow-up, there is no difference between the two treatment arms, regardless of stratification. Treatment was well tolerated with few adverse effects." 97-13 - Breast, Skin Toxicity - Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation. chapter link 11121627 (2000): No difference 97-12 (1998-2002) - SCLC - Phase I. Dose escalation AHRT with concurrent cisplatin/etoposide. chapter link 15890573 (2005): MTD 61.2 Gy 97-08 (1997-1999) - Endometrium - Phase II. Post-operative chemo+RT for "high risk" (Stage IC-III). EBRT + concurrent cisplatin, BT followed by cisplatin + taxol x 4 cycles. 16545437 (2006), 15093913 (2004) 97-06 (1998-2000) - Bladder - Phase I/II trial. Operable muscle-invading. TURBT followed by cisplatin + BID RT followed by either selective bladder preservation or radical cystectomy and adjuvant chemotherapy. chapter link 14529770 (2003) 97-05 - Lung - Phase II. Surgery + paclitaxel/carboplatin + concurrent RT chapter link 15908657 (2005) - Good OS 97-04 / Intergroup (1998-2002) - Pancreas - pre and post chemoradiation with 5-FU vs Gemcitabine for adjuvant treatment of resected pancreatic cancer 18319412 ASCO 2006 Abstract (Regine et al) - http://meeting.jco.org/cgi/content/abstract/24/18_suppl/4007 97-03 (Closed 1999) - Head & Neck - Phase II. Advanced Stage III-IV. Randomized to 1) 70 Gy / 7 weeks with daily cisplatin and 5-FU during the last 10 days of RT; 2) 70 Gy / 13 weeks every other week with concurrent daily hydroxyurea and 5-FU ; 3) 70 Gy / 7 weeks with weekly cisplatin and paclitaxel. 15254053, 2004 (Preliminary results) Abstract (Long term results, 2007) 97-02 (Intergroup, CALGB 9343) - Breast - lumpectomy + tamoxifen +/- RT for women > 70 15342805 97-01 Protocol (PDF) - NSCLC - Phase III. Randomized chemo/RT vs RT alone for Stage IIIA-IIIB. Closed for poor accrual in 1999 96-16 (CALGB 9633) - NSCLC - Phase III. Resected T2N0 lung +/- adjuvant chemotherapy 18809614 (2008) 96-12 Protocol (PDF) - Vulva - Phase II, chemoradiation (5-FU + Mitomycin). Locally advanced (not treatable by radical vulvectomy). Closed - poor accrual 96-10 - H&N - Phase II. Reirradiation + chemotherapy in unresectable recurrent H&N chapter link 17764087 (2008): Feasible approach, acceptable acute and late effects 96-09 Protocol (PDF) - SCLC - Phase II. "Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer 15939930 (2005) 96-08 (closed) - Prostate - Pathologically LN+. Indefinite AST +/- 70.2 Gy EBRT 96-01 (closed) - Prostate - Post-op RT +/- Casodex 150 mg x 2 years for pT3 with PSA elevation. 95-17 (1997-2000) - Breast - Phase I-II. Brachytherapy, LDR or HDR. Toxicity: 16503383 (2006) 95-14 (1997-2000) Protocol (PDF) - Sarcoma - Preoperative RT - MAID - RT. chapter link 16446334 (2006): Activity, but too toxic 95-11 Protocol (PDF) (CALGB 9334) - Sclerosis of pleural effusion by talc thoracoscopy vs talc slurry 15764775 (2004): Similar in efficacy 95-08 - CNS - 1-3 brain mets, randomized WBRT +/- radiosurgery - survival advantage for 1 met. 15158627 (2004) Full text 95-07 - CNS - GBM. Phase I. RT + Topotecan. 11181676 (2001) 95-06 (1995-1997) - Bladder - Phase I/II. BID chemo/RT after TURBT. Cisplatin + 5-FU. chapter link 11110598 (2000) 95-05 - H&N - Basic science. Evaluation of NPC patients for tumor angiogenesis by microvessel density 15708253 (2005): No difference in survival based on MVD <60 vs MVD >=60 95-01 - H&N - Protocol (PDF) - Post-op. RT +/- chemo for high risk. 94-17 (1995-97) - CNS - GBM. Phase II. RT 60 Gy + tirapazamine (3x/week x 12). Two dose levels. 10715295 (2002) 94-15 / INT 0146 / NCCTG 93-46-53 (1994-2001) - Colon - Laparoscopic colectomy vs open colectomy. 94-13 (1995-99) - Prostate - High risk (>15%) of LN+. Neoadjuvant/concurrent vs adjuvant hormones; and whole-pelvic vs prostate only RT. 12743142 (2003) 94-10 - Lung - NSCLC medically inoperable or unresectable, Stage II-IIIB. Randomized to sequential chemo/RT vs one of two concurent chemo/RT arms (std or hyperfractionated). 94-09 ECOG E4592 - NSCLC - Ancillary study to RTOG 91-05 / ECOG E3590 / INT 0115. Laboratory / Clinical correlative studies. 94-08 (closed) - Prostate - Intermediate risk localized PCA. AST/2 followed by EBRT vs. EBRT alone. 94-06 (closed) - Prostate - Phase I, 3D-CRT dose escalation, 68.4 - 79.2Gy. Conclusion level V (78 Gy in 2 Gy/fx) ASTRO Abstract : "The rate of grade 3+ toxicity from 3DCRT with 78 Gy in 2.0 Gy fractions remains better than expected compared to historical controls. However, low-grade late toxicity is significantly higher in dose level V than dose level III. These differences may be dose and/or volume related." Conclusion level IV (74 Gy in 2 Gy/fx) 14967428 : "Tolerance to three-dimensional conformal radiotherapy with 74 Gy in 2-Gy fractions remains better than expected compared with historical controls. The magnitude of any effect from fraction size requires additional follow-up." 94-05 - Esophagus - high (64.8 Gy) versus standard (50.4 Gy) dose Chapter link No difference in survival or loco-regional control 94-04 - Lung - RT 60/30 +/- interferon beta 11955727 - Conclusion: "This multicenter, controlled Phase III trial failed to confirm the efficacy of Betaseron in patients receiving definitive radiotherapy for locally advanced, nonmetastatic non-small-cell lung cancer. The use of beta-interferon led to greater rates of both acute and late treatment-related toxicity." 94-03 / INT 0144 / SWOG 9304 (1994-2000) Protocol - Rectum - Phase III. Post-op chemo/RT. 3-arm: 1) bolus 5-FU -> RT + PVI 5-FU -> bolus 5-FU 2) PVI 5-FU -> RT + PVI 5-FU -> PVI 5-FU 3) bolus 5-FU + leucovorin + levamisole -> RT + bolus 5-FU + LV -> bolus 5-FU + LV + Lev 94-02 / INT 0149 (1994-2002) - CNS, pure and mixed anaplastic oligodendroglioma. RT +/- neoadj PCV. 16782910 (2006) 94-01 / INT 0147 - Rectum - preoperative vs postoperative chemo/RT Closed due to poor accrual 93-12 (1994-1996) - SCLC - Phase II. LS-SCLC, AHFX 45/30 BID with concurrent cisplatin/ifosfamide chapter link 10944132 (2000): As effective as cisplatin/etoposide, but more toxicity 93-11 - NSCLC - Dose escalation for NSCLC chapter link 15667949 (2005): MTD 83.3 Gy (V20 <25%) or 77.4 Gy (V20 26-35%) 93-10 (1994-1997) - CNS Lymphoma - Phase II, chemo->RT chapter link 12488408, 2002 - HD-MTX based regimen combined with consolidative RT is superior to RT alone when the overall survival data are compared to historical data. However, patients over age 60 had significant risk of late toxicity from the combined treatment. 93-09 (Intergroup 0139) - Lung - Randomized Trial of Chemoradiotherapy to 61 Gy [no S] versus Chemoradiotherapy to 45 Gy followed by Surgery [S] Using Cisplatin Etoposide in Stage IIIa Non-small Cell Lung Cancer (NSCLC): Intergroup Trial 0139, RTOG (9309) chapter link Abstract ASTRO 2003 Video Presentation — Turrisi et al. 19632716 (2009) 93-05 - CNS - Malignant gliomas, EBRT with BCNU +/- radiosurgery - no change in survival. 15465203 — "Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol." Souhami et al. Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60. 93-02 - Melanoma - post-op H&N melanoma, 30 Gy/5 fx (twice/week) vs observation. Closed due to poor accrual (20 pts enrolled). 92-10 - Cervix - positive para-aortic LNs. HFx RT + concurrent 5-FU / cisplatin. 11704321 (2001) 92-08 - Anal - RT dose escalation, split course 18472363 (2008): Split-course worse outcomes compared with historical controls 92-07 - Esophagus - brachytherapy boost Swallowing function: 11693897 — "Swallowing function and weight change observed in a phase I/II study of external-beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 9207)." Gaspar et al. Cancer J. 2001 Sep-Oct;7(5):388-94. Final report: 10699886 Full Text — "A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report." Gaspar et al. Cancer. 2000 Mar 1;88(5):988-95. Preliminary report: 9112458 Full Text — "A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report." Gaspar et al. Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):593-9. 92-05 - Lung - accelerated hyperfractionation 10776986 — "Accelerated hyperfractionation for bronchogenic cancer: Radiation Therapy Oncology Group 9205." Herskovic et al. Am J Clin Oncol. 2000 Apr;23(2):207-12. 92-04 - Lung - Phase II, randomized induction chemo + concurrent chemo/RT vs concurrent chemo + hyperfractionated RT 12062596 (2002) 92-02 (1992-95) - Prostate - long-term (AST/2 + EBRT + 2 years AST) versus short-term (AST/2 + EBRT) androgren suppression; locally advanced. chapter link 18413638 (2008): LT-ADT better than ST-ADT, but survival difference only for GS 8-10 91-16 - Bladder - Pilot Study of the Quality of Life of Bladder Cancer Patients Being Treated on the Companion Protocol RTOG-8903 chapter link 91-15 - H&N - Phase III. Stage I-II. Chemoprevention with isotretinoin to prevent second malignant tumors. chapter link 16595780: No benefit 91-14 - CNS - High grade glioma. Quality of life and neuropsychological evaluation. 9211998 (1997) 91-12 - Cervix - A RANDOMIZED COMPARISON OF 5FU INFUSION + BOLUS CISPLATIN AS AN ADJUNCT TO RADIATION THERAPY, VS RADIATION ALONE IN SELECTED PATIENTS WITH STAGE 1-A2,1B,IIA, CARCINOMA OF THE CERVIX FOLLOWING RADICAL HYSTERECTOMY AND NODE DISSECTION 10764420 (2000) 91-11 - H&N - Larynx preservation: Induction Chemotherapy/XRT vs Concomitant Chemo/XRT vs XRT alone chapter link 12525193 (2003): Chemo-RT superior over induction chemo-RT or RT alone 14645636 (2003): Salvage laryngectomy acceptable complication rate 91-08 - H&N - Role of p105 as a predictor of outcome from prior RTOG protocols 7913703 (1994): Flow cytometry evaluation for p105 and DNA may be predictive 91-06 - Lung - Phase II. Inoperable NSCLC. BID RT with concurrent daily oral etoposide + IV cisplatin. 8648357 (1996) 91-05 (INT 0115) ECOG E3590 Protocol (PDF) - Lung - post-op chemo/RT vs post-op RT. chapter link 11071672 (2000): No difference in OS or LC 91-04 - CNS - Brain mets, unresected RPA class 1-2, compared 54.4 Gy BID boost vs 30 Gy in 10 fx. 9336134 — "A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104." Murray KJ et al. Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):571-4. 91-03 Protocol - NSCLC - PFTs and serum markers evaluated after RT 90-20 (closed) - Prostate - Phase II. EBRT + Etanidazole. Conclusion 8948352 : "Results of this trial regarding PSA response and clinical disappearance of disease are similar to historical controls and do not warrant further investigation of etanidazole as was done in this trial." 90-19 (closed) - Prostate - High risk post-RP patients (ECE, SV+, SM+). RP +/- adjuvant EBRT. chapter link 17538167 (2006): Improved PSA and clinical RFS, no impact on DM-RFS 90-15 - Lung - Unresectable NSCLC. Phase I/II BID RT + concurrent chemotherapy. 7712445 (1995) 90-12 - Esophagus - Phase II. High dose RT chapter link 10078631 Conclusion: high dose tolerable 90-05 - CNS - Radiosurgery, maximum tolerated dose, for brain mets and primary brain tumors. Established 24 Gy, 18 Gy, and 15 Gy for tumors < 2 cm, 2.1-3 cm, and 3.1-4 cm. First report: 8621289 (1996), Final report: 10802351 (2000) 90-03 - H&N - Compare Daily Hyperfractionation, Accelerated Hyperfractionation with a Split, Accelerated Fractionation with Concomitant Boost, and Standard Fractionation Radiotherapy for Squamous Cell Carcinomas of the Head and Neck chapter link 10924966 (2000): HF or CB better than standard fractionation; split course AF comparable 90-01 (1990-97) - Cervix - Pelvis+Paraaortic RT vs Pelvic RT + Chemo 10202164 (1999), 2002 ASTRO Plenary #1, 14990643 (2004) 80-XX to 89-XX 89-05 - CNS - Brain mets. RT +/- bromodeoxyuridine . 7673021, 1995 89-03 - Bladder - T2-T4a. Bladder preservation. Randomized to +/- MCV before RT + cisplatin. chapter link 9817278 89-02 - Rectum - Local excision for distal rectal CA. chapter link 10661337 (2000): Feasible, but high failure rate for T2/T3 89-01 - NSCLC - Phase III. pN2. Induction chemo followed by 1) surgery vs 2) RT. chapter link 12243809 (2002), 18257399 (2008) - QOL 88-24 - H&N - post-op concurrent chemo/RT (phase II, not randomized) 9128951 88-23 (closed) - Liver - Phase I/II. Unresectable HCC. Induction CT/RT, followed by intra-arterial cisplatin and I-131 Antiferritin Conclusion 9612600 "Patients with unresectable alpha-fetoprotein-positive hepatocellular carcinoma experienced improved survival and decreased toxicity when managed with post-induction cycles of intra-arterial cisplatin as compared with intravenous doxorubicin and 5-FU. Intravenous 131I-polyclonal antiferritin did not improve survival when added to either post-induction regimen but dramatically increased hematologic toxicities." 88-22 (closed) - Palliation - Prostate or Breast bone mets. Dose-escalated fractionated hemibody irradiation 8823257 : "The maximum tolerated dose of fractionated (2.50 Gy) HBI was found to be 17.5 Gy. The major dose limiting toxicity was hematological (thromboleukopenia). There was not a significant dose response effect on occult disease (appearance of new disease) or in the requirement for additional treatment, although certain trends were noted for the higher doses. When only patients completing assigned HBI from RTOG 82-06 and 88-22 were compared, there was no difference in the time to new disease or additional treatment in the treated field. Based on the investigative parameters of this study, single high-dose HBI was as effective as fractionated HBI." 88-17 (Intergroup 0099) - H&N - Nasopharynx chemo/RT vs RT (Al-Sarraf) chapter link 9552031: Superior survival for concurrent chemo-RT 88-15 (INT 0096) - SCLC - Phase III. Standard RT 45/25 vs. AHFX 45/30 BID. Concurrent cisplatin/etoposide chapter link 9920950 (1999): Hyperfractionated regimen better OS 88-14 - Bladder - Phase II. Neoadjuvant Chemotherapy with MCV (MTX/CDDP/VBL) with Intraoperative Electron Beam Radiotherapy and Pre- and Postoperative External Beam Radiotherapy in Patients with Invasive Bladder Carcinoma chapter link 88-09 - H&N - Phase I/II, comparing two accelerated fractionation: Split course 1.6 Gy BID to 67.2 Gy, 2 week break after 38.4 Gy vs. 1.8 Gy + 1.5 Gy concomitant boost for last 11 fractions to 70.5 Gy chapter link 7790243: both arms can be used successfully 88-08 / ECOG 4588 - NSCLC - Unresectable Stage II-IIIB. std RT vs induction chemo/RT vs hyperfractionated RT. 7707407 (1995), 10669675 (2000) 88-06 - CNS lymphoma - Phase I/II. HIV-negative CNS lymphoma treated with CHOD x 2 -> WBRT to 41.4 Gy boosted to 59.4 Gy. 8636771 (1996) 88-04 - NSCLC - Phase II. Unresectable. Induction/concurrent vinblastine + cisplatin. 1313202 (1992), SCLV mets - 10386642 88-02 - Bladder - Operable T2-T4a . Bladder preservation. chapter link 8558186 (1996) 87-05 - Hyperthermia - Phase I/II. Radiotherapy and Hyperthermia in Patients with Selected Measurable Superficial Tumors 8256760 87-04 - Anal - Phase III. RT + 5-FU + Mitomycin vs RT + 5-FU chapter link 8823332 (1996): Use of Mitomycin necessary 87-03 - Hyperthermia - Phase I/II. Combined Modality Therapy with DDP and Regional Hyperthermia in Patients with Malignancies of the Pelvis and Lower Abdomen 86-12 - CNS - IUdR 8407393 (1993), 8985039 (1996) 86-10 (closed) - Prostate - Concurrent and adjuvant Zoladex + Flutamide with XRT. Bulky primary disease (>25 cc) 18172188 (2008) Conclusion 11483335 : "In patients with Gleason score 2--6 carcinoma of the prostate, a short course of androgen ablation administered before and during radiotherapy has been associated with a highly significant improvement in local control, reduction in disease progression, and overall survival." 86-09 - Neutron Therapy cancer.gov link - Phase III 86-08 - Rectum, Cervix, Bladder - Phase I/II. WR-2721 Administered Before Protracted Fractionated Radiotherapy in Patients with Cancer of the Rectum, Cervix, or Bladder 85-31 (closed) - Prostate - N+ or cT3/pT3, Zoladex at time of radiation vs radiation alone. Excluded bulky disease (see 86-10) unless there was +LN outside of pelvis. Conclusion 15817329 : "In a population of patients with unfavorable prognosis carcinoma of the prostate, androgen suppression applied as an adjuvant after definitive RT was associated not only with a reduction in disease progression but in a statistically significant improvement in absolute survival. The improvement in survival appeared preferentially in patients with a Gleason score of 7-10." 85-30 - H&N - Standard surgery +/- cricopharyngeal myotomy chapter link 10488976: No benefit 85-28 - CNS - solitary brain met, Phase I/II, dose escalation with hyperfractionated boost. 8435812 — "Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28." Epstein BE et al. Cancer. 1993 Feb 15;71(4):1362-7. 8330997 NOTE:Countered by 91-04 85-27 - H&N - etanidazole + XRT chapter link 7790241: no difference 85-12 - Bladder - T2-4. Bladder preservation. chapter link 8478228 (1993) 85-06 - Bile Duct - Phase I/II. Unresected, resected but residual, or locally recurrent biliary duct cancer. Intra-op RT (14-22 Gy) followed by EBRT (45-50 Gy). 2/8 pts alive at publication w/ median follow-up 10.5 months 1514529 -- Intraoperative radiation therapy of extrahepatic biliary carcinoma: a report of RTOG-8506. (Wolkov HB, Am J Clin Oncol. 1992 Aug;15(4):323-7.) 85-03 (INT 0034) - H&N - Post-op RT vs. post-op cisplatin/5-FU then RT chapter link 1618662: No benefit 85-02 (1985-89) - Gyn / Palliation - Phase I/II? Palliation for advanced pelvic malignancies. 3.7 Gy BID to 44.4 Gy with break after 4th and 8th fractions. Break duration randomized 2 vs 4 wks. chapter link 8083097 (1994), 7679668 (1993), 2476426 (1989) 85-01 - Esophagus - XRT alone vs XRT/Chemo - increased OS for T1-3 N0-1 M0 squamous cell and adenocarcinomas Update: Abstract Full text — "Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group." Cooper et al. JAMA. 1999 May 5;281(17):1623-7. First report: Abstract — "Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus." Herskovic et al. N Engl J Med. 1992 Jun 11;326(24):1593-8. Race: Abstract: Does Race Influence Survival? — "Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?" Streeter et al. Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1047-52. 84-19 - Protocol Recurrent or persistent tumors -- Phase III Randomized Study of Interstitial Thermoradiotherapy vs Interstitial Radiotherapy Alone for Metastatic, Recurrent, or Persistent Tumors 8600093 (1996): No benefit as delivered 84-12 / GOG 71 (1984-91) - Cervix - TREATMENT OF PATIENTS WITH SUB-OPTIMAL (BULKY) STAGE 1B CARCINOMA OF THE CERVIX. A RANDOMIZED OF RADIATION THERAPY VS RADIATION PLUS ADJUVANT EXTRAFACIAL HYSTRECTOMY 12798694, 2003 - Keys 84-11 - H&N, Breast, Sarcoma - Phase III Randomized Comparison of Radiotherapy plus Hyperthermia vs Radiotherapy Alone in the Treatment of Patients with Head and Neck Carcinoma, Breast Cancer, or Soft Tissue Sarcoma Amenable to Potentially Curable Radiotherapy 84-07 (1984-89) - Lung NSCLC - Phase I/II, concomitant boost: 45 Gy/1.8 (daily) + 18 Gy/10 fx (2-3x/week) = 63 Gy; escalate to 50.4 + 19.8 Gy = 70.2 Gy / 5.5 wks or 45 + 25.2 = 70.2 Gy / 5 wks. 7836079, 1993 84-05 (closed) - Liver - Phase I/II dose escalation, GI liver mets, whole liver RT 1.5 Gy BID escalated to 27, 30, 33, 36 Gy (not reached). Conclusion: 8365932 "The study design could not credibly establish a safe dose for hepatic irradiation, however, it did succeed in determining that 33 Gy in fractions of 1.5 Gy is unsafe, carrying a substantial risk of delayed radiation injury. The absence of apparent late liver injury at the 27 Gy and 30 Gy dose levels suggests that a prior clinical trial of adjuvant hepatic irradiation in patients with resected colon cancer may have employed an insufficient radiation dose (21 Gy) to fully test the question." RTOG 84-03 - Lung NSCLC / PCI - RT alone vs RT + PCI for NSCLC (non-metastatic). 1651304, 1991 83-19 (closed) - Liver - Phase III. HCC. CT/RT Induction followed 1 month later by CT +/- 131-I-Antiferritin Conclusion 9612600: "Intravenous 131-I-polyclonal antiferritin did not improve survival when added to either post-induction regimen but dramatically increased hematologic toxicities." 83-15 (1983-87) - CNS Lymphoma - Phase II. RT alone, 40 Gy WBRT + 20 Gy boost. 1572835, 1992 83-14 - Anal - Phase II. RT + 5-FU + Mitomycin chapter link 2724350 (1989): Effective 83-13 (1983-1987) - H&N - hyperfractionation dose escalation: 1.2 Gy BID to 67.2 Gy, 72.0 Gy, 76.8 Gy, 81.6 Gy 2180866 (Preliminary): Higher LC with 72.0 and 76.8 Gy hyperfractionated, led to RTOG 90-03 7790242 (Long-term): No increase in late toxicity 83-12 - Lung NSCLC - Phase I/II, T3-T4 NSCLC. Concomitant boost at 1.8 Gy/fx to 50.4 Gy (elective nodal). Primary tumor to 2.68 Gy/day to total of 75 Gy in 28 fx. 7860394 (1995) 83-11 - Lung NSCLC - Phase I/II dose escalation, randomized to 1.2 Gy BID to 60.0, 64.8, 69.6 Gy, 74.4 Gy or 79.2 Gy. 2167952 (1990) 83-03 - Bladder - Phase I/II. Dose escalation 60.0 Gy, 64.8 Gy, or 69.6 Gy. Evaluation of Twice-Daily Fractional Radiotherapy for Locally Advanced Stage B/C/D Transitional Cell and Unresectable Squamous Cell Carcinoma of the Bladder chapter link 3058657 (1988): Good tolerance to hyperfractionation 83-07 (closed) - Prostate - XRT + DES vs XRT + Megace - similar results but different toxicities Conclusion 7721614 : "The results of the study indicate comparable efficacy (using tumor clearance as an end point) of DES and Megestrol. Although DES appears more effective in suppressing testosterone, it is also associated with a higher incidence of drug-related toxicity." 83-05 - Melanoma - dose per fraction. 4 x 8.0 Gy (32 Gy) once weekly vs 20 x 2.5 Gy (50 Gy) 5 days/week. 1995527 — "Fraction size in external beam radiation therapy in the treatment of melanoma." Sause WT et al. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):429-32. 83-02 (1983-89) - CNS - Phase I/II. High grade gliomas. Dose-escalation of hyperfractionated or accelerated HF RT with BCNU. 8608540 (1996), 8380567 (1993), 1451073 (1992) 83-01 (closed) - Liver - Phase I/II. HCC. Induction CT+RT, followed 1 month later by 131-I-antiferritin + CT Conclusion 2415692: "These studies have demonstrated the toxicity and therapeutic activity of 131I antiferritin and the emerging role of radiolabelled antibody in cancer therapy." 82-06 (closed) - Palliation - Bone mets. 30 Gy EBRT +/- 8 Gy hemibody irradiation Conclusion 1374061 : "This clinical trial demonstrates that HBI has the potential to be used to treat systemic and occult metastases, particularly if both halves of the body can be treated." 81-17 - H&N - Piloted RT + chemo. Standard RT with concomitant cisplatin (100 mg/m2) q3weeks x 3 courses. Included oropharynx, nasopharynx, oral cavity. chapter link 3802013 and 2224782: Concurrent cisplatin + RT safe and effective; led to RTOG 91-11 81-16 - H&N - Phase I/II. Induction cisplatin/5-FU + surgery + RT (42 patients) or surgery + sequential cisplatin/5-FU + RT (29 patients) chapter link 1998567: No difference between induction or sequential chemo 81-10 - Bladder - Phase III Photon vs Mixed Beam Preoperative Radiotherapy for Stage B/C/D Carcinoma of the Bladder chapter link 81-08 - Lung NSCLC - feasibility study of hyperfractionated RT 1650526 (1991) 81-06 - Bladder - Phase III Randomized Comparison of Sandwich vs Standard Preoperative Adjuvant Radiotherapy in Stage B/C Bladder Cancer chapter link 81-05 - Bladder - Phase I/II Misonidazole and Radiotherapy for Inoperable Bladder Cancer chapter link 80-05 (1980-84) - Cervix - RT +/- misonidazole link to text. Negative trial 3104249 (prelim, 1987), 10348279 (final results, 1999) 80-03 (closed) - Liver - Phase III. Liver mets. RT +/- radiosensitization with misonidazole 3597149: No benefit 70-XX to 79-XX 79-28 (closed) - Liver - Phase I/II. 131-I-Antiferrin, Liver RT and ADR/5-FU Conclusion: 6275989 - "Present results suggest that further clinical studies with isotopic immunoglobulin are indicated." 79-20 (1979-86) - Cervix - Pelvic only vs Pelvic + Paraaortic RT. 2211198 (1990), 7616634 (1995) 79-16 (1979-83) - CNS - Brain mets. Randomized to 30/10 vs 30 Gy/6 fx/3 wks, and +/- misonidazole 1993631 79-15 - H&N - Misonidazole chapter link Hemoglobin concentration - 2689395 (1989) 79-13 - H&N - Hyperfractionated 1.2 Gy BID vs. standard fractionation chapter link 3542916: No difference, worse acute toxicity 79-05 (1979-82) - Gyn/Palliative - 10 Gy x 3 courses, 4-wk apart chapter link 2442127 (1987) 79-04 - H&N - Hypofractionated RT +/- Misonidazole chapter link 2646255: No difference 78-26 - Bladder - Photon Radiotherapy vs Pion Radiotherapy for Transitional Cell Carcinoma of the Urinary Bladder chapter link 78-21 - Bladder - Phase I/II Radiosensitization with Misonidazole plus Radiotherapy for Bladder Cancer chapter link 7180834 78-17 - Hypoxia - Phase II Study of Misonidazole plus Intraoperative Radiotherapy for Nonresectable Carcinomas 78-16 - Hyperthermia - Phase I-II Hyperthermia (43.5 Degrees Centigrade) Before and After Radiation Treatment for Human Tumors 78-10 (closed) - Palliation - Bone mets. Hemibody dose escalation Conclusion: 2423225 - "HBI achieves pain relief sooner and with less evidence of pain recurrence in the irradiated area than conventionally treated patients. The most effective and safest of the HBI doses tested were 600 rad for the upper HBI and 800 rad for the lower or mid-HBI." 78-04 - Bladder - Adjuvant Radiotherapy before and after Surgery for Bladder Cancer chapter link 3967204 78-03 - H&N - Phase I/II. Induction cisplatin + bleomycin prior to RT 6159067: Low morbidity but not very effective 78-02 - H&N - Phase II. Misonidazole pilot trial chapter link 7333912: 67% CR rate in Stage III-IV 77-08 - H&N - PI/II. Advanced patients. Induction VCR+Bleo+MTX 6180625: satisfactory result 77-06 (closed) - Prostate - Prostate field vs. Whole pelvis + prostate boost. Stage A2-B, N0. Conclusion: 3058656 - "The results of the study revealed no statistically significant benefit of elective pelvic irradiation. 77-05 - Bladder - Radiotherapy with Neutrons Alone or with Photons with or without Surgery for Urinary Bladder Cancer chapter link 6375854 77-03 - H&N - Phase I/II. Hyperfractionation pilot: 1.25 Gy BID and 1.5 Gy BID chapter link 1.2 Gy BID tolerable; 1.5 Gy BID too toxic. Led to RTOG 79-13 76-19 - H&N - Registry study chapter link 2674073: Risk of second primary cancers 15% at 5 years 76-15 - H&N - Phase I-II. Neoadjuvant and concurrent chemo-RT (VBM=VCR,Bleo,MTX) Too toxic 76-13 - H&N - Phase I-II. Combined multidrug chemo/RT (Cytoxan,VCR,Bleo) + adjuvant chemo 85493: Too toxic 76-12 - Bladder - Preoperative or Postoperative Radiotherapy or Radiotherapy Alone for Clinical Stage B1 or B2 or C Bladder Carcinoma chapter link 76-08 - Cervix - Phase III. Photons vs. photons + neutrons No difference 76-06 (1976-79) - CNS - Brain mets, favorable patient population (controlled primary, no extracranial mets). Rand to 30/10 vs 50/20 6171553 76-05 (closed) - Liver - Phase I. Treatemnt of liver mets with RT 75-06 (closed) - Prostate - Pelvis XRT +/- periaortic nodes 3494005 74-02 - Bone metastases - Solitary 40.5/15 vs. 20/5; Multiple 30/10 vs. 15/5 vs. 20/5 vs. 25/5 6178497 (1982) 74-01 / ECOG 1374 - CNS - High grade glioma. 1) 60 Gy whole brain vs 2)60 Gy + 10 Gy boost vs 3)60 Gy + BCNU vs 4)60 Gy + CCNU + DTIC 3281031 (1988) 73-61 (1973-76) - CNS - Brain mets. Various doses: 20/5, 30/10, 40/15. Ultra-rapid: 6 Gy x 2. (RTOG 69-01 and 73-61 are grouped together.) 6154024, 6174490, 6169424 73-03 (1973-79) - H&N - Pre-op 50 Gy vs Post-op 60 Gy RT. chapter link 3449477: Post-op better 73-02 - Lung NSCLC - T4 or N3 (IIIB). Palliation. Randomized to 30 Gy, 40 Gy continuous, or 40 Gy split. 2579938 (1985) 73-01 - Lung NSCLC - Stage III. Randomized to 40 Gy split course or 40 Gy, 50 Gy, or 60 Gy continuous. 6998937 (1980 - patterns of tumor recurrence) 71-05 - Cervix - Phase III. Stage IIB-IVA. Randomized to RT 51/30 vs. split course 25/10 + 25/10. Both followed by BT boost 30 Gy LDR chapter link 6406397: No difference 71-04 - Bladder - Phase III. Stage C or D1. Randomized to RT 60/30 vs. split course 27.5/10 + 27.5/10 4050737: No difference 71-03 - H&N - Phase III. Nasopharynx. Randomized to RT 66/33 vs. split course 30/10 + 30/10 chapter link 6993442: No difference 71-02 - H&N - Phase III. Base of tongue. Randomized to RT 66/33 vs. split course 30/10 + 30/10 chapter link 6343309: No difference 71-01 - H&N - Phase III. Tonsillar fossa. Randomized to RT 66/33 vs. split course 30/10 + 30/10 chapter link 8213620: No difference 70-02 - H&N - Phase III. RT +/- Carbogen chapter link 120869: No difference 70-01 - Cervix - Phase III. RT vs. Hypofractionated RT + Hyperbaric Oxygen chapter link 7028700: No difference Pre 70-XX 69-01 (1971-73) - CNS - Brain mets. Various doses: 30/10, 30/15, 40/15, 40/20. Ultra-rapid: 10 Gy x 1. (RTOG 69-01 and 73-61 are grouped together.) 6154024, 6174490, 6169424 68-01 (1968-1972) - H&N - Phase III. Stage III-IV OC, OP, SGL, HP. Randomized to RT alone vs. induction MTX followed by RT chapter link 7410127: No benefit